COHANCE.NS Profit & Loss
Cohance Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹13.40 Bn | ₹10.51 Bn | ₹11.98 Bn | ₹22.69 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹0.46 Bn | ₹0.62 Bn | ₹0.59 Bn | ₹0.34 Bn | OtherIncome |
| Total Income | ₹13.87 Bn | ₹11.13 Bn | ₹12.56 Bn | ₹23.03 Bn | Income |
| Cost of Materials Consumed | ₹4.30 Bn | ₹2.66 Bn | ₹2.23 Bn | ₹7.05 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-0.21 Bn | ₹0.49 Bn | ₹0.83 Bn | ₹-0.43 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹1.11 Bn | ₹1.36 Bn | ₹2.50 Bn | ₹5.08 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹0.05 Bn | ₹0.07 Bn | ₹0.12 Bn | ₹0.37 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹0.48 Bn | ₹0.55 Bn | ₹0.77 Bn | ₹1.87 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹2.54 Bn | ₹1.95 Bn | ₹2.68 Bn | ₹6.71 Bn | OtherExpenses |
| Total Expenses | ₹8.27 Bn | ₹7.08 Bn | ₹9.12 Bn | ₹20.66 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹5.60 Bn | ₹4.06 Bn | ₹3.44 Bn | ₹2.37 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹-0.29 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹5.60 Bn | ₹4.06 Bn | ₹3.44 Bn | ₹2.07 Bn | ProfitBeforeTax |
| Tax Expense | ₹1.48 Bn | ₹1.05 Bn | ₹0.79 Bn | ₹0.57 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹4.11 Bn | ₹3.00 Bn | ₹2.65 Bn | ₹1.50 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | N/A | ₹0.00 Bn | ₹2.68 Bn | ₹1.79 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹16.16 | ₹11.80 | ₹10.52 | ₹4.69 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹16.16 | ₹11.80 | ₹10.45 | ₹4.68 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from COHANCE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).